119 related articles for article (PubMed ID: 37220017)
21. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi FS; Wolchok JD; Schadendorf D; Larkin J; Long GV; Qian X; Saci A; Young TC; Srinivasan S; Chang H; Tang H; Wind-Rotolo M; Rizzo JI; Jackson DG; Ascierto PA
Cancer Immunol Res; 2021 Oct; 9(10):1202-1213. PubMed ID: 34389558
[TBL] [Abstract][Full Text] [Related]
22. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
23. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
24. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
25. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
Mao Y; Gide TN; Adegoke NA; Quek C; Maher N; Potter A; Patrick E; Saw RPM; Thompson JF; Spillane AJ; Shannon KF; Carlino MS; Lo SN; Menzies AM; da Silva IP; Long GV; Scolyer RA; Wilmott JS
J Transl Med; 2023 Apr; 21(1):257. PubMed ID: 37055772
[TBL] [Abstract][Full Text] [Related]
26. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
Betof AS; Nipp RD; Giobbie-Hurder A; Johnpulle RAN; Rubin K; Rubinstein SM; Flaherty KT; Lawrence DP; Johnson DB; Sullivan RJ
Oncologist; 2017 Aug; 22(8):963-971. PubMed ID: 28476944
[TBL] [Abstract][Full Text] [Related]
27. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
28. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
[TBL] [Abstract][Full Text] [Related]
29. The Predictive Value of
Ye T; Zhang JY; Liu XY; Zhou YH; Yuan SY; Yang MM; Xie WZ; Gao C; Chen YX; Huang ML; Ye CZ; Chen J
Front Immunol; 2021; 12():785526. PubMed ID: 35069558
[TBL] [Abstract][Full Text] [Related]
30. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
31. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
Li T; Zhang C; Zhao G; Zhang X; Hao M; Hassan S; Zhang M; Zheng H; Yang D; Liu L; Mehraein-Ghomi F; Bai X; Chen K; Zhang W; Yang J
Cancer Lett; 2020 May; 477():19-30. PubMed ID: 32120023
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
da Silveira Nogueira Lima JP; Georgieva M; Haaland B; de Lima Lopes G
Cancer Med; 2017 Jun; 6(6):1143-1153. PubMed ID: 28463413
[TBL] [Abstract][Full Text] [Related]
33. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
34. Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy.
Dong Y; Gao Q; Chen Y; Zhang Z; Du Y; Liu Y; Zhang G; Li S; Wang G; Chen X; Liu H; Han L; Ye Y
Nat Commun; 2023 May; 14(1):2540. PubMed ID: 37137884
[TBL] [Abstract][Full Text] [Related]
35. Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.
Nakamura Y; Namikawa K; Kiniwa Y; Kato H; Yamasaki O; Yoshikawa S; Maekawa T; Matsushita S; Takenouchi T; Inozume T; Nakai Y; Fukushima S; Saito S; Otsuka A; Fujimoto N; Isei T; Baba N; Matsuya T; Tanaka R; Kaneko T; Onishi M; Kuwatsuka Y; Nagase K; Onuma T; Nomura M; Umeda Y; Yamazaki N
Eur J Cancer; 2022 Nov; 176():78-87. PubMed ID: 36194906
[TBL] [Abstract][Full Text] [Related]
36. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Budczies J; Denkert C; Győrffy B; Schirmacher P; Stenzinger A
BMC Med Genomics; 2017 Dec; 10(1):74. PubMed ID: 29212506
[TBL] [Abstract][Full Text] [Related]
37. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
38. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Khattak MA; Reid A; Freeman J; Pereira M; McEvoy A; Lo J; Frank MH; Meniawy T; Didan A; Spencer I; Amanuel B; Millward M; Ziman M; Gray E
Oncologist; 2020 Mar; 25(3):e520-e527. PubMed ID: 32162809
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Drug Resistance in Melanoma.
Winder M; Virós A
Handb Exp Pharmacol; 2018; 249():91-108. PubMed ID: 28275910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
